The Limits Of REMS: Opioid Debate Shows Shortcomings Of New FDA Powers

An FDA advisory committee's discussion of an agency proposal to manage the risk of long-acting/extended release opioids underscores the limits of the agency's authority to curb misuse of prescription medications even with the new safety powers enshrined in the 2007 renewal of the user fee legislation

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet